UNSPSC 51372807: Quadazocine mesylate

This classification denotes an opioid receptor agonist and opiate antagonist with the molecular formula C25H37NO2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 582SS143QX, chemically known as 3-pentanone, 1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-, (2r-(2.alpha.,6.alpha.,11s*))-, methanesulfonate (salt), but more generally known as quadazocine mesylate, which bears US NIH Compound Identifier 3052769.

UNSPSC 51372807 Quadazocine mesylate, a Commodity code, shows minimal recent state and local procurement activity. The single identified opportunity — Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems — does not align with the code's nominal scope of quadazocine mesylate, an opioid antagonist pharmaceutical. The opportunity solicits naloxone (a different opioid antagonist) and safe drug deactivation equipment, not quadazocine mesylate specifically. This mismatch suggests either misclassification in the county's procurement system or that state and local buyers are not actively procuring quadazocine mesylate under this code at present.

Seminole County, Florida released IFB60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems through quarterly deliveries to the Seminole County Community Health Building in Sanford. The county's e-Procurement Portal submission requirement, fixed-fee pricing structure, and potential FEMA funding introduce standard compliance obligations including drug-free workplace certification, E-Verify authorization, and federal environmental regulations. The contract carries an initial two-year term with a one-year renewal option and a three-month probationary period allowing termination without cause. The code shows no other recent state or local opportunities, indicating low procurement volume or systematic undercoding in this pharmaceutical category.